325 related articles for article (PubMed ID: 36911717)
1. The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy.
Kang C; Liu L; Wu C; Li L; Jia X; Xie W; Chen S; Wu X; Zheng H; Liu J; Li R; Zeng B
Front Immunol; 2023; 14():1111369. PubMed ID: 36911717
[TBL] [Abstract][Full Text] [Related]
2. Purinergic signalling in brain ischemia.
Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Adenosine (eAdo) - A
Thapa A; Abdelbaset-Ismail A; Chumak V; Adamiak M; Brzezniakiewicz-Janus K; Ratajczak J; Kucia M; Ratajczak MZ
Stem Cell Rev Rep; 2022 Dec; 18(8):2893-2911. PubMed ID: 35870082
[TBL] [Abstract][Full Text] [Related]
4. Extracellular ATP and adenosine: The Yin and Yang in immune responses?
Faas MM; Sáez T; de Vos P
Mol Aspects Med; 2017 Jun; 55():9-19. PubMed ID: 28093236
[TBL] [Abstract][Full Text] [Related]
5. Purinergic Signaling Within the Tumor Microenvironment.
Draganov D; Lee PP
Adv Exp Med Biol; 2021; 1270():73-87. PubMed ID: 33123994
[TBL] [Abstract][Full Text] [Related]
6. Complementary Role of P2 and Adenosine Receptors in ATP Induced-Anti-Apoptotic Effects Against Hypoxic Injury of HUVECs.
Feliu C; Peyret H; Poitevin G; Cazaubon Y; Oszust F; Nguyen P; Millart H; Djerada Z
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909368
[TBL] [Abstract][Full Text] [Related]
7. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
8. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
10. Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Kotulová J; Hajdúch M; Džubák P
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830449
[TBL] [Abstract][Full Text] [Related]
11. Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment.
Chiarella AM; Ryu YK; Manji GA; Rustgi AK
Trends Cancer; 2021 Aug; 7(8):731-750. PubMed ID: 34074623
[TBL] [Abstract][Full Text] [Related]
12. New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2.
Baraldi PG; Romagnoli R; Tabrizi MA; Bovero A; Preti D; Fruttarolo F; Moorman AR; Borea PA
Farmaco; 2005 Mar; 60(3):185-202. PubMed ID: 15784237
[TBL] [Abstract][Full Text] [Related]
13. Purinergic mechanisms in neuroinflammation: An update from molecules to behavior.
Beamer E; Gölöncsér F; Horváth G; Bekő K; Otrokocsi L; Koványi B; Sperlágh B
Neuropharmacology; 2016 May; 104():94-104. PubMed ID: 26384652
[TBL] [Abstract][Full Text] [Related]
14. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.
Morrone FB; Jacques-Silva MC; Horn AP; Bernardi A; Schwartsmann G; Rodnight R; Lenz G
J Neurooncol; 2003 Sep; 64(3):211-8. PubMed ID: 14558596
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Adenosine Triphosphate (eATP) and Its Metabolite, Extracellular Adenosine (eAdo), as Opposing "Yin-Yang" Regulators of Nlrp3 Inflammasome in the Trafficking of Hematopoietic Stem/Progenitor Cells.
Ratajczak MZ; Kucia M
Front Immunol; 2020; 11():603942. PubMed ID: 33584673
[TBL] [Abstract][Full Text] [Related]
16. Extracellular nucleotide and nucleoside signaling in vascular and blood disease.
Idzko M; Ferrari D; Riegel AK; Eltzschig HK
Blood; 2014 Aug; 124(7):1029-37. PubMed ID: 25001468
[TBL] [Abstract][Full Text] [Related]
17. ATP stimulates peripheral axons in human, rat and mouse--differential involvement of A(2B) adenosine and P2X purinergic receptors.
Irnich D; Tracey DJ; Polten J; Burgstahler R; Grafe P
Neuroscience; 2002; 110(1):123-9. PubMed ID: 11882377
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cytokine-mediated JNK signalling by purinergic P2Y
Ng PY; McIntosh KA; Hargrave G; Ho KH; Paul A; Plevin R
Cell Signal; 2018 Nov; 51():59-71. PubMed ID: 30076967
[TBL] [Abstract][Full Text] [Related]
19. Purinergic receptor activation inhibits mitogen-stimulated proliferation in primary neurospheres from the adult mouse subventricular zone.
Stafford MR; Bartlett PF; Adams DJ
Mol Cell Neurosci; 2007 Aug; 35(4):535-48. PubMed ID: 17553694
[TBL] [Abstract][Full Text] [Related]
20. ATP-induced in vivo neurotoxicity in the rat striatum via P2 receptors.
Ryu JK; Kim J; Choi SH; Oh YJ; Lee YB; Kim SU; Jin BK
Neuroreport; 2002 Sep; 13(13):1611-5. PubMed ID: 12352612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
